Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

NCT05876221 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT05876221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05876221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Lead sponsor
University of Cologne
Phase
Observational
Overall status
Completed
Start date
October 30, 2023
Completion date
March 30, 2025
Enrollment
223 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired thrombotic thrombocytopenic purpura